Skip to main content

Advertisement

Open Peer Review Reports for: Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
7 Feb 2018 Submitted Original manuscript
6 Apr 2018 Author responded Author comments - Hans Salwender
Resubmission - Version 2
6 Apr 2018 Submitted Manuscript version 2
23 Aug 2018 Reviewed Reviewer Report - Wilson I. Gonsalves
30 Jan 2019 Reviewed Reviewer Report - Sarah Holstein
19 Feb 2019 Author responded Author comments - Hans Salwender
Resubmission - Version 3
19 Feb 2019 Submitted Manuscript version 3
24 Feb 2019 Author responded Author comments - Hans Salwender
Resubmission - Version 4
24 Feb 2019 Submitted Manuscript version 4
6 Mar 2019 Author responded Author comments - Hans Salwender
Resubmission - Version 5
6 Mar 2019 Submitted Manuscript version 5
3 Apr 2019 Author responded Author comments - Hans Salwender
Resubmission - Version 6
3 Apr 2019 Submitted Manuscript version 6
Publishing
12 Apr 2019 Editorially accepted
28 May 2019 Article published 10.1186/s12885-019-5600-x

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement